

IN THE CLAIMS:

1-20. (Cancelled).

21. (Currently Amended). A method of slowing mucopolysaccharidosis ~~mucopolysaccharide~~ disease progression in a patient in need thereof comprising administering an inhibitor of glucosylceramide synthase in an efficacious amount to slow mucopolysaccharidosis ~~mucopolysaccharide~~ disease progression in a patient, wherein the inhibitor of glucosylceramide synthase is ~~an imino-sugar~~ N-butyldeoxynojirimycin.

22. (Currently Amended). The method according to claim 21 wherein the mucopolysaccharidosis ~~mucopolysaccharide~~ disease is selected from the group consisting of MPS I (MPS IH, IS or IH/S), MPS II, MPS IIIA, IIIB, IIIC or IIID, MPS IVA or IVB, MPS VI and MPS VII.

23-27. (Canceled).

28. (Currently Amended). A method of reducing neuronal glycolipid storage in mucopolysaccharidosis ~~mucopolysaccharide~~ disease in a patient in need thereof comprising administering an inhibitor of glucosylceramide synthase in an efficacious amount to reduce neuronal glycolipid storage in mucopolysaccharidosis ~~mucopolysaccharide~~ disease in a patient, wherein the inhibitor of glucosylceramide synthase is ~~an imino-sugar~~ N-butyldeoxynojirimycin.

29. (Currently Amended). The method according to claim 28 wherein the mucopolysaccharidosis ~~mucopolysaccharide~~ disease is selected from the group consisting of MPS I (MPS IH, IS or IH/S), MPS II, MPS IIIA, IIIB, IIIC or IIID, MPS IVA or IVB, MPS VI and MPS VII.

30-35. (Canceled).

36. (Currently Amended). A method of reducing pathological features resulting from glycolipid accumulation in a patient with a mucopolysaccharidosis ~~mucopolysaccharide~~ disease comprising administering an inhibitor of glucosylceramide synthase in an efficacious amount to reduce pathological features resulting from glycolipid accumulation in a patient with a mucopolysaccharidosis ~~mucopolysaccharide~~ disease, wherein the inhibitor of glucosylceramide synthase is ~~an imino-sugar~~ N-butyldeoxynojirimycin.

37. (Currently Amended). A method for improving survival of a patient with a mucopolysaccharidosis ~~mucopolysaccharide~~ disease comprising administering an inhibitor of glucosylceramide synthase in an efficacious amount to improve survival of a patient with

mucopolysaccharidosis ~~mucopolysaccharide~~ disease, wherein the inhibitor of glucosylceramide synthase is ~~an imino-sugar~~ N-butyldeoxynojirimycin.

38. (New). A method of slowing mucopolysaccharidosis disease progression in a patient in need thereof comprising administering an inhibitor of glucosylceramide synthase in an efficacious amount to slow mucopolysaccharidosis disease progression in a patient, wherein the inhibitor of glucosylceramide synthase is N-butyldeoxygalactonojirimycin.

39. (New). The method according to claim 38, wherein the mucopolysaccharidosis disease is selected from the group consisting of MPS I (MPS IH, IS or IH/S), MPS II, MPS IIIA, IIIB, IIIC or IIID, MPS IVA or IVB, MPS VI and MPS VII.